| Schedule of Segment Information |
Selected financial information for the
Company’s operating segments is as follows:
| |
|
Three Months Ended March 31, |
|
| |
|
2018 |
|
|
2017 |
|
| Net revenues – External |
|
|
|
|
|
|
|
|
| Clinical Laboratory Operations |
|
$ |
45,586 |
|
|
$ |
684,265 |
|
| Hospital Operations |
|
|
1,556,075 |
|
|
|
- |
|
| |
|
$ |
1,601,661 |
|
|
$ |
684,265 |
|
| |
|
|
|
|
|
|
|
|
| (Loss) income from operations |
|
|
|
|
|
|
|
|
| Clinical Laboratory Operations |
|
$ |
(756,083 |
) |
|
$ |
(1,292,275 |
) |
| Hospital Operations |
|
|
(1,472,600 |
) |
|
|
(467,316 |
) |
| Corporate |
|
|
(1,483,341 |
) |
|
|
(1,804,517 |
) |
| Eliminations |
|
|
- |
|
|
|
7,851 |
|
| |
|
$ |
(3,712,024 |
) |
|
$ |
(3,556,257 |
) |
| Depreciation and amortization |
|
|
|
|
|
|
|
|
| Clinical Laboratory Operations |
|
$ |
295,474 |
|
|
$ |
434,468 |
|
| Hospital Operations |
|
|
37,728 |
|
|
|
- |
|
| Corporate |
|
|
314 |
|
|
|
312 |
|
| Eliminations |
|
|
- |
|
|
|
(7,851 |
) |
| |
|
$ |
333,515 |
|
|
$ |
426,929 |
|
| Capital expenditures |
|
|
|
|
|
|
|
|
| Clinical Laboratory Operations |
|
$ |
- |
|
|
$ |
(100,382 |
) |
| Hospital Operations |
|
|
- |
|
|
|
1,090,922 |
|
| |
|
$ |
- |
|
|
$ |
990,540 |
|
***` Intersegment revenues are eliminated
in consolidation.
| |
|
March 31, 2018 |
|
|
December 31, 2017 |
|
| Total assets |
|
|
|
|
|
|
|
|
| Clinical Laboratory Operations |
|
$ |
1,019,946 |
|
|
$ |
1,503,520 |
|
| Hospital Operations |
|
|
2,788,059 |
|
|
|
2,549,504 |
|
| Corporate |
|
|
3,510,297 |
|
|
|
3,436,773 |
|
| Assets of AMSG and HTS classified as held for sale |
|
|
243,963 |
|
|
|
255,566 |
|
| Eliminations |
|
|
(1,424,496 |
) |
|
|
(1,454,570 |
) |
| |
|
$ |
6,137,769 |
|
|
$ |
6,290,794 |
|
|